First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
Domingo P, Suárez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, Vidal F, Muñoz A, Viciana P, Lozano F, Vergara A, Roca B, García Alcalde ML, Cosín J, Terrón A, Galindo MJ, Geijo P, Ribera E, Gonzalez J, Sanchez T, Lacalle JR, Garrido M.
Domingo P, et al. Among authors: torres f.
J Antimicrob Chemother. 2008 Jun;61(6):1348-58. doi: 10.1093/jac/dkn121. Epub 2008 Mar 20.
J Antimicrob Chemother. 2008.
PMID: 18356150
Clinical Trial.